Repare Therapeutics Target of Unusually High Options Trading (NASDAQ:RPTX)

Repare Therapeutics Inc. (NASDAQ:RPTX) saw unusually large options trading on Wednesday. Investors bought 3,187 call options on the company. This represents an increase of approximately 407% compared to the average daily volume of 629 call options.

Wall Street Analyst Weigh In

RPTX has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Repare Therapeutics in a research report on Monday. Cowen cut shares of Repare Therapeutics to a “hold” rating in a research note on Monday, November 17th. TD Cowen downgraded shares of Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 17th. HC Wainwright decreased their target price on shares of Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Finally, Wall Street Zen raised shares of Repare Therapeutics to a “hold” rating in a research report on Saturday, November 15th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $3.00.

Institutional Trading of Repare Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in RPTX. Acadian Asset Management LLC boosted its holdings in shares of Repare Therapeutics by 35.6% in the first quarter. Acadian Asset Management LLC now owns 640,332 shares of the company’s stock valued at $624,000 after buying an additional 168,230 shares during the period. Rangeley Capital LLC acquired a new stake in shares of Repare Therapeutics during the second quarter worth $494,000. Affinity Asset Advisors LLC lifted its position in Repare Therapeutics by 100.0% in the 1st quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company’s stock valued at $197,000 after acquiring an additional 100,000 shares in the last quarter. Militia Capital Partners LP acquired a new position in Repare Therapeutics in the 2nd quarter worth $166,000. Finally, Squarepoint Ops LLC bought a new position in Repare Therapeutics during the 3rd quarter worth about $115,000. Institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Trading Up 17.7%

Shares of RPTX traded up $0.39 during trading hours on Wednesday, hitting $2.56. 14,213,543 shares of the stock traded hands, compared to its average volume of 409,888. The business has a fifty day moving average of $2.00 and a 200-day moving average of $1.74. The firm has a market capitalization of $110.15 million, a PE ratio of -1.51 and a beta of 1.02. Repare Therapeutics has a 1-year low of $0.89 and a 1-year high of $2.66.

Repare Therapeutics (NASDAQ:RPTX) last announced its quarterly earnings data on Friday, November 14th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.43. The firm had revenue of $11.62 million for the quarter, compared to the consensus estimate of $7.50 million. As a group, equities research analysts expect that Repare Therapeutics will post -2.04 earnings per share for the current fiscal year.

Repare Therapeutics Company Profile

Repare Therapeutics, traded on NASDAQ under the symbol RPTX, is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology medicines. The company applies synthetic lethality—a concept whereby cancer-specific genetic vulnerabilities are exploited—to design small-molecule therapies that selectively kill tumor cells while sparing healthy tissue. Repare’s proprietary functional genomics and screening platform integrates CRISPR-based assays and computational biology to systematically uncover novel genetic interactions and therapeutic targets.

At the core of Repare’s approach is its ability to identify and validate DNA damage response (DDR)-related targets.